Get the Stockscreener App
2.22
1.37%
0.03
Mei Pharma Inc stock is traded at $2.22, with a volume of 1,125.
It is up +1.37% in the last 24 hours and up +8.82% over the past month.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
See More
Previous Close:
$2.19
Open:
$2.16
24h Volume:
1,125
Relative Volume:
0.13
Market Cap:
$14.88M
Revenue:
$105.38M
Net Income/Loss:
$17.78M
P/E Ratio:
0.8315
EPS:
2.67
Net Cash Flow:
$-50.48M
1W Performance:
+3.02%
1M Performance:
+8.82%
6M Performance:
-21.28%
1Y Performance:
-23.45%
1-Day Range:
$2.075
$2.2345
1-Week Range:
$2.06
$2.2345
52-Week Range:
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
Name
Mei Pharma Inc
Sector
Industry
Phone
858-369-7100
Address
11455 EL CAMINO REAL, SAN DIEGO, CA
Compare MEIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.2345 | 14.66M | 105.38M | 17.78M | -50.48M | 2.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.78 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.72 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.00 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.30 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Downgrade | Laidlaw | Buy → Hold |
| Mar-25-22 | Downgrade | Jefferies | Buy → Hold |
| Mar-25-22 | Downgrade | Stifel | Buy → Hold |
| Mar-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-03-22 | Initiated | Jefferies | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-29-20 | Initiated | SunTrust | Buy |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Jul-27-18 | Upgrade | Stifel | Hold → Buy |
| Jul-13-18 | Initiated | SunTrust | Buy |
| Apr-18-16 | Reiterated | Wedbush | Neutral |
| Mar-23-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-18-14 | Reiterated | ROTH Capital | Buy |
| Oct-16-14 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
| Oct-22-13 | Reiterated | Stifel | Buy |
| Apr-15-13 | Initiated | Stifel | Buy |
View All
Mei Pharma Inc Stock (MEIP) Latest News
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
MEI Pharma Reports Significant Revenue Decline - TipRanks
MEIP Explores Strategic Options to Enhance Shareholder Value | M - GuruFocus
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - GuruFocus
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
Inside Buffett’s $334B Cash Pile: Get Ready for Berkshire Hathaway Earnings - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Sharp Co. (OTCMKTS:SHCAY) Short Interest Down 25.8% in March - The AM Reporter
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
Billionaire David Tepper’s Top 10 Stock Picks - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Will the Stock Market Crash As President Trump's Tariffs Take Effect? History Offers a Clue. - The Globe and Mail
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Cautious Investors Should Wait for THIS Entry Point Before Buying Nvidia Stock - The Globe and Mail
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
Mei Pharma Inc Stock (MEIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):